** Shares of Grifols GRLS.MC jump 9% after the Spanish drugmaker reported H1 results ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business
** The company booked a net profit of 177 million euros ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says
** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg
** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year
** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say
** Share price is at its highest in 1.6 years, outperforming the IBEX35 index .IBEX, which falls 0.6%
($1 = 0.8650 euros)
(Reporting by Mireia Merino)
((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.